Kornimate/medical-research-clean huggingface dataset:
effect of autologous blood patch injection versus biosentry hydrogel tract plug in the reduction of pneumothorax risk following lung biopsy procedures

Conditions: Lung Biopsy

Summary: the purpose of this study is to compare two methods that are currently used at the end of a ct guided lung biopsy to close the hole on the surface of the lung in order to minimize the chance of air leaking out of the hole. the two techniques consist of either injecting a very small amount of your the blood called a blood patch into the biopsy hole or injecting a gel-based fda approved artificial plug called biosentry that will eventually get absorbed into the body.

this study will determine the rate of all pneumothoraces and those pneumothoraces requiring treatment following percutaneous lung biopsy in patients who have received abpi or biosentry at the end of the biopsy procedure. the data collected will be used to determine if there is equal effectiveness in the reduction of pneumothorax rates from both interventions.

Eligibility criteria:
inclusion criteria: * ≥18 years of age * referred for ct guided biopsy of lung lesion * target lesion of any size * target lesion located 1.5 cm or more away from visceral pleura based on the needle path * skin thickness ≤7 cm (from skin to pleura) * needle path without transgression of pleural fissure bleb, or bulla is possible * coaxial biopsy technique using angiotech 19-gauge introducer needle * needle length ≤15 exclusion criteria: * passage through non-aerated lung or tissue * more than 1 biopsy on the same side requiring more than 1 pleural puncture * history of prior ipsilateral lung interventions including: * chest tube placement * surgery * pleurodesis * radiation treatment

Keywords: experimental: autologous blood patch injection (abpi) experimental: biosentry (formerly known as bio-seal) hydrogel tract plug 14-141
neoplasia detection with methylene blue mmx tablets in patients with uc undergoing colonoscopy

Conditions: Ulcerative Colitis

Summary: evaluation of the intraepithelial neoplasia detection rate in patients with long standing ulcerative colitis undergoing mucosal staining with oral methylene blue mmx tablets prior to colonoscopy.


Eligibility criteria:
inclusion criteria: * endoscopically verified uc signed written informed consent exclusion criteria: * known or suspected gi obstruction or perforation liver or renal impairment, malignancy, pregnancy or lactation, suppressed pt.
quantitative assessment of blood supply in the gastic conduit with fluorescence angiography for esophageal reconstruction

Conditions: Esophageal Squamous Cell Carcinoma

Summary: a single-institution, randomize controlled trial is to be held to evaluate the correlation between blood supply in the gastic conduit and the incidence of anastomotic fistula during radical operation for esophageal squamous cell carcinoma by fluorescence angiography.


Eligibility criteria:
inclusion criteria: * 1.histologically confirmed esophageal squamous cell carcinoma and and potential resection; * 2.intend to undergo thoracic laparoscopy combined with three-incision esophageal cancer radical operation; * 3.the stomach is used as an esophageal substitute for reconstruction; * 4.enrolled patients will adopt the esophagus bed pathway and round neck anastomosis method; * 5.have a performance status of 0 or 1 on the ecog performance scale; adequate organ function; * 6.be willing and able to provide written informed consent/assent for the trial. exclusion criteria: * 1.histologically confirmed non-squamous cell carcinoma of the esophagus ; * 2.the ecog score of patient's physics \>1; * 3.patients who use other organs instead of the esophagus; * 4.patients with vascular arch injury and need vascular anastomosis; * 5.patients with multiple complications such as heart disease or diabetes; * 6.other patients whom the medical practitioner considers inappropriate for inclusion.

Keywords: esophageal squamous cell carcinoma blood supply anastomotic fistula fluorescence angiography
utilizing battlefield acupuncture(bfa) to treat chronic pain for homeless and at risk veterans.

Conditions: Acupuncture; Homelessness; Pain; Veterans

Summary: this research study will evaluate the effectiveness of utilizing battlefield acupuncture (bfa) on homeless and at risk for homelessness veterans with chronic pain for 12 weeks.

methodology: this is a mixed methods prospective design study. a total of 35 subjects will be recruited for this study. the primary study outcome variables are: pain level- pre and post treatment, stress, mood and usual activity levels, sleep patterns and behavioral factors such as ; anxiety, depression, suicidal ideation, substance use and housing stability. 4. findings: pending 5. clinical relationships: this study is conducted to demonstrate whether or not bfa treatment will decrease pain and improve quality of life for homeless and at risk for homelessness veterans. 6. impact/significance: pending

Eligibility criteria:
inclusion criteria: eligibility criteria include: * they are 18 years or older * they are homeless or at risk for homelessness veterans who are enrolled in the va bedford healthcare system and registered in one of the hud-vash or hchv programs, * history of chronic pain. * availability to participate in the study for 4 months. if they meet these criteria, they will be asked to complete the informed consent to enroll in the study. exclusion criteria: * female veterans who are pregnant * history of bleeding disorders or currently on blood thinning medications * currently being treated for an active infection of the outer ear. * currently have a picc line in their body or are receiving iv antibiotics. * fear of needles/tacks * undiagnosed pain complaint our recruitment plan invites all eligible veterans and is just, fair, and equitable.
brain stimulation for epilepsy long term follow-up

Conditions: Epilepsy

Summary: the purpose of this study is to collect subject data to evaluate the rate of sudden unexplained death in epilepsy (sudep) with bilateral neurostimulation of the anterior nucleus of the thalamus in people diagnosed with refractory epilepsy. the data obtained from the physician initiated studies will be pooled with data collected in medtronic-sponsored studies to assess sudep risk.

medtronic is conducting a pivotal clinical trial entitled stimulation of the anterior nucleus of the thalamus in epilepsy (santé). one of the requirements of the santé study is to evaluate the rate of sudden unexplained death in epilepsy (sudep). medtronic is aware of approximately 18 subjects with various types of epilepsy that have been treated with neurostimulation of the anterior nucleus of the thalamus outside the santé trial under five physician-sponsored studies. this protocol will initially collect information regarding the physician-sponsored study subjects' status. the goal of this study is to pool these data with the santé data for the purpose of estimating the sudep rate. this is a multi-center, retrospective and prospective clinical study in patients previously implanted with devices that provide bilateral neurostimulation of the anterior nucleus of the thalamus during non-medtronic-sponsored studies.

Eligibility criteria:
inclusion criteria: * have received bilateral an stimulation of the anterior nucleus of the thalamus (an) for epilepsy or are receiving it at the time of enrollment * for patients with therapy active at the time of enrollment, ability of the patient or legal representative to understand and provide signed consent for participating in the study * for patients with therapy permanently discontinued or died at time of enrollment, the irb/reb has approved a waiver allowing collection of the data or the ability of the patient or legal representative to understand and provide signed consent/medical authorization exclusion criteria: * none

Keywords: epilepsy sudep dbs
delirium prevention with ketamine in ear, nose, and throat (ent) patients

Conditions: Otolaryngeal Cancer

Summary: the goal of this prospective randomized double blinded placebo controlled study is to investigate if a single dose of ketamine in addition to standard anesthesia will reduce the risk of delirium in otolaryngeal cancer patients postoperatively. ketamine's effect on post-operative pain and opioid use will be measured as well. electroencephalogram (eeg) will be utilized during the surgical procedure to evaluate its potential as a possible predictive device for delirium.

this is a single center prospective randomized double blinded placebo controlled study. the primary aim of the study is to optimize the intraoperative treatment protocol for head and neck cancer patients to reduce the incidence of delirium and associated postoperative cognitive dysfunction. secondary aims are to determine the dose response relationship for intraoperative ketamine and delirium reduction, determine if a single dose of ketamine will reduce post-operative pain and opioid requirements, determine if raw electroencephalogram (eeg) data can predict postoperative delirium during general anesthesia, and to evaluate length of intensive care unit (icu) and length of hospital stay. participants will be randomized to one of three groups after administration of general anesthesia; one dose of .5 mg/kg intravenous (iv) ketamine, 1.0 mg/kg of iv ketamine, or iv placebo. an eeg will be used during the surgical procedure to gather raw data for off line analysis among patients developing post-operative delirium.

Eligibility criteria:
inclusion criteria: * current diagnosis of otolaryngeal cancer and undergoing surgery with general anesthesia * competent to provide informed consent exclusion criteria: * emergency surgery * monitored anesthesia care (i.e., regional anesthesia alone without plans for general anesthesia) * surgery involving the eye, eyebrow, forehead, or frontal scalp near the sensor placement * poor health literacy * allergy, or have experienced any drug reaction to ketamine * pregnant or lactating * currently in active alcohol withdrawal * taking buprenorphine for chronic pain

Keywords: anesthesiology
association of non-alcoholic fatty liver disease and diabetes mellitus

Conditions: Non-alcoholic Fatty Liver Disease (NAFLD)

Summary: this study will evaluate the association of non-alcoholic fatty liver disease and diabetes mellitus. patients presenting in our clinic with diabetes mellitus type 1 or 2 will receive the following examination: * transient elastography and controlled attenuation parameter using the fibroscan * blood examination including biochemical markers the statistically calculated sample size needed is 340 patients.


Eligibility criteria:
inclusion criteria: * male or female, 18 years and older * written informed consent * diabetes mellitus type 1 or 2 exclusion criteria: * patients with mental diseases * pregnancy or lactation * ascites * continued alcohol consumption (\> 21 drinks/week for male and \> 14 drinks/week for female patients) * chronic liver disease (viral hepatitis, autoimmune hepatitis, pbc, psc, hemochromatosis, m wilson) * hepatocellular carcinoma/ liver metastasis
change and clinical significance of plantar fascia thickness after eswt

Conditions: Plantar Fasciitis

Summary: the aim of the study is to investigate the effect of extracorporeal shock wave therapy (eswt) on the thickness of plantar fascia measured by ultrasonographic examination among patients with chronic plantar fascitis. the change of plantar fascia thickness will be correlated with clinical improvement.

the aim of the study is to investigate the effect of extracorporeal shock wave therapy (eswt) on the thickness of plantar fascia measured by ultrasonographic examination among patients with chronic plantar fascitis. two different dosage of eswt will be applied, and the outcome will be followed 3 and 6 months after the treatment. the change of plantar fascia thickness will be correlated with clinical improvement, including the pain improvement, foot function, and quality of life at follow up.

Eligibility criteria:
inclusion criteria: * diagnosed as plantar fasciitis for at least 6 months * refractory to other conservative treatments exclusion criteria: * acute infection of soft tissue/bone * malignancy * epiphysiolysis in the focus * blood coagulation disorders * pregnancy * patients with pacemaker * foot deformity * autoimmune disorders-related arthropahy * sciatica * previous treatment with eswt

Keywords: plantar fasciitis ultrasonographic examination
increasing walking following cardiac rehabilitation

Conditions: Cardiac Diseases; Walking

Summary: the purpose of the project was to test the widely endorsed assumption that pedometers produce or encourage more physical activity participation in the form of walking. the investigators hypothesized that pedometers would not increase the amount of walking cardiac patients participated in after their cardiac rehabilitation program compared to patients without pedometers.

as evidenced by the media attention given to pedometers and recent physical activity promotional efforts focused on pedometers, people seem to think that owning a pedometer will influence activity levels. however, an examination of a few social cognitive theories produces no theoretical rationale that would support any sustained positive influence of pedometers in the absence of some other conditional factor, such as a behavioural goal or a social support system. we believe that once people determine how many steps their usual routes and daily activity typically amounts to, that the pedometer will no longer be used. we based our contentions on two theories: self efficacy theory (bandura, 1986;1997) and self-determination theory (deci \& ryan, 2000).

Eligibility criteria:
inclusion criteria: * all patients referred to the northern alberta cardiac rehabilitation program * patients who are willing to participate * are able to read english * patients who are able to walk at 2.0 mph based on their exercise stress test results exclusion criteria: * patients unable to walk or walking contra-indicated * unwilling * do not read english

Keywords: exercise adherence cardiac patients walking
motivational interview for daily living activities in elderly people undergoing total knee replacement

Conditions: Motivation; Behavior, Health; Nursing Caries; Nurse's Role

Summary: purpose: in this study, it was aimed to examine the effect of motivational interview on daily living activities on physical adaptation and quality of life in elderly people who underwent total knee replacement.it was aimed to examine the effect of motivational interview on daily living activities on physical adaptation and quality of life in elderly people who underwent total knee replacement. design: the research was planned as a pretest, posttest, randomized controlled study in order to determine the effect of the motivational interviews on the life quality and physical activity of old patients. h1: after total knee replacement, the target for daily living activities is higher than the patients who applied the hand and those who did not. h2: patients with targeted daily living activities with total knee replacement begin to get used to it and begin earlier than those who do not.


Eligibility criteria:
inclusion criteria: * those aged 65 and over, * having total knee replacement, * the non-spiritual system (the peasant of the sick), * a person who can read and write can cope at a level that prevents conversation, * first time system add-on, * they are viewed as agreeing to participate in the research. exclusion criteria: * neurological (such as dementia) and psychiatric (such as schizophrenia) medical diagnoses that affect cognitive status * patients who did not participate in the motivational interviews and who wanted to leave the study were determined.

Keywords: motıvatıonal ıntervıew total knee prosthesıs old age quality of life physical compatibility
real world use and outcomes of vascade closure device versus manual compression in patients with cfa disease

Conditions: Common Femoral Artery Stenosis

Summary: to study the patient characteristics and outcomes associated with the real-world use of manual compression vs. vascular closure devices (vcds) after common femoral artery (cfa) percutaneous access for coronary and endovascular interventions. an institutional procedural database, based on electronic medical record information will be abstracted to collect this information.

the overall objective of the study will be to examine the safety and efficacy of the vascade closure device compared to manual compression (standard of care) to achieve hemostasis after endovascular procedures requiring access within a severely diseased cfa. this study will be a retrospective single center review of 200 patients undergoing endovascular procedures utilizing vascular access within a severely diseased cfa between 2018 and 2020 at yale new haven hospital. a random selection of patients undergoing hemostasis with manual compression (n = 100) and vascade vascular closure system (n = 100) will be conducted. the two groups will then be statistically compared with respect to 48-hour and 30-day safety and efficacy outcomes.

Eligibility criteria:
inclusion criteria: 1. 5, 6 or 7 fr access within the cfa 2. act \< 300 seconds 3. age 18 - 90 years old 4. severe common femoral arterial disease percent stenosis \> 50, which will be core-lab adjudicated exclusion criteria: 1. ipsilateral cfa access within 30 days preceding or subsequent to the index case 2. prior ipsilateral closure device use, other than vascade 3. high bleeding risk act \> 300 or \> 250 with iib/iiia inhibitor plt \ 1.7 on the day of procedure inherent coagulopathy noac, warfarin, or lovenox administered within 24 hours of the procedure 4. suspected intraluminal thrombus, dissection, pseudoaneurysm, hematoma, or av fistula
a safety, efficacy, and tolerability trial of pregabalin as add-on treatment in pediatric subjects <4 years of age with partial onset seizures.

Conditions: Partial Onset Seizures

Summary: this study is designed to evaluate the effectiveness of 2 doses of pregabalin to reduce seizure frequency as an add on therapy in pediatric subjects 1 month to \<4 years of age with refractory partial onset seizures. it is hypothesized that both doses of pregabalin will demonstrate superior efficacy when compared to placebo by reducing the partial onset seizure frequency and that pregabalin will be safe and well tolerated.


Eligibility criteria:
inclusion criteria: * subject must have 3 partial onset seizures in the month prior to screening. * subject must have 2 partial onset seizures during the 48 hour baseline phase. * signed informed consent. * on 1-3 stable anti-epileptic drugs at screening. exclusion criteria: * primary generalized seizures including clonic, tonic, clonic-tonic, absence, febrile seizures, and infantile spasms. * lennox-gasteau, bects, and dravet's syndrome. * status epliepticus within 1 year of screening. * any change in aed regimen with 7 days of screening. * progressive structural central nervous system (cns) lesion or a progressive encephalopathy. * progressive errors of metabolism.

Keywords: partial onset seizures epilepsy safety efficacy tolerability pregabalin lyrica adjunctive treatment placebo controlled blinded eligibility criteria
raman spectroscopy and skin cancer

Conditions: Skin Cancer; Basal Cell Carcinoma; Squamous Cell Carcinoma

Summary: the goal of this observational study is to find out if raman spectroscopy, a type of imaging, can be used to determine the size of skin cancer tumors. the main question it aims to answer is: -can raman spectroscopy help figure out how far a tumor spreads? this study will take measurements using laser light from an experimental, handheld probe by lightly touching the skin.

radiation therapy is an alternative to surgery for localized tumors with excellent tumor control and cosmetic outcome. raman spectroscopy has potential to be a useful non-invasive, non-destructive, real-time, in-vivo tool for differentiation of cancerous vs. non-cancerous tissues. with this knowledge and future studies, this will ultimately guide skin brachytherapy more accurately and avoid unnecessary radiation to cosmetically and functionally important tissues including eyelid, nose, lips or skin folds. the purpose of this study is to determine the feasibility of raman spectroscopy to identify microscopic infiltration extent of skin cancer beyond grossly visible tumor, using artificial intelligence methods of supervised and un-supervised machine learning algorithms, including pattern recognition, convolutional neural networks, k-means clustering and principal component analysis.

Eligibility criteria:
inclusion criteria: * histologically confirmed skin cancer (either basal cell carcinoma or squamous cell carcinoma) * participants must plan to receive brachytherapy treatment for the skin cancer at the study site. * ability to provide consent to the study. exclusion criteria: * patient belongs to a vulnerable population (minors (under 18 years old), adults unable to consent, prisoners). * lesions on the eyelid or in close proximity to the eye * pregnant women, or women of childbearing age who refuse pregnancy testing. * patient has pacemaker.
a study to evaluate the effect of hepatic impairment on jnj-42847922 in adult participants

Conditions: Healthy; Hepatic Impairment

Summary: the purpose of this study is to evaluate the pharmacokinetics (pk) of a single oral dose of jnj-42847922 in adult participants with hepatic impairment when compared to healthy participants with normal hepatic function.


Eligibility criteria:
inclusion criteria: all * be a man or woman 18 to 79 years of age, inclusive participants with normal hepatic function * generally healthy * must not exceed upper limit of normal limits for serum bilirubin, transaminase levels, albumin levels, prothrombin time (pt), and international normalized ratio (inr) when measured at screening and day 1 participants with (mild, moderate or severe) hepatic impairment * medically stable * total child-pugh score of 5 or 6, inclusive (mild); or 7 to 9, inclusive (moderate); or 10 to 15, inclusive (severe) as determined by the investigator * stable hepatic function during screening and those measured on day 1 * stable renal function exclusion criteria: participants with normal hepatic function * hepatitis b surface antigen (hbsag) or hepatitis c antibodies at screening participants with (mild, moderate or severe) hepatic impairment * severe ascites or pleural effusion; prothrombin time greater than (\>)18 seconds; evidence of progressive liver disease within the previous 4 weeks, as indicated by changes in hepatic transaminases, alkaline phosphatase, and gamma-glutamyl transferase * history of hepatopulmonary syndrome, hydrothorax, or significant hepatorenal syndrome * acute or exacerbating hepatitis, fluctuating or rapidly deteriorating hepatic function as indicated by widely varying or worsening of clinical and/or laboratory signs of hepatic impairment in the judgment of either the investigator or the sponsor's medical monitor * clinically significant laboratory findings except as related to hepatic impairment